ASCO 2017 Press Releases

ASCO 2017: New Technology Dives Deep Into the Cancer Genome- An Initial Step Toward Blood Tests for Early Detection of Cancer

Chicago, IL (UroToday.com) In a study of 124 patients with advanced breast, lung, and prostate cancers, a new, high-intensity genomic sequencing approach detected circulating tumor DNA at a high rate. In 89% of patients, at least one genetic change detected in the tumor was also detected in the blood. Overall, 627 (73%) genetic changes found in tumor samples were also found in blood samples with this approach.

ASCO 2017: Abiraterone Delays Metastatic Prostate Cancer Growth by 18 Months, Extends Survival

Chicago, IL (UroToday.com) Adding abiraterone acetate (Zytiga) plus prednisone to standard hormonal therapy for men newly diagnosed with high-risk, metastatic prostate cancer lowers the chance of death by 38%. In a phase III clinical trial of 1,200 men, abiraterone also more than doubled the median time until the cancer worsened, from 14.8 months to 33 months.

ASCO 2017: Abiraterone Slows Advanced Prostate Cancer, Helps Patients Live Longer

Chicago, IL (UroToday.com) A clinical trial of nearly 2,000 men shows that adding abiraterone acetate (Zytiga) to a standard initial treatment regimen for high-risk, advanced prostate cancer lowers the relative risk of death by 37%. The 3-year survival rate was 76% with standard therapy alone, but 83% with standard therapy plus abiraterone. This is the largest study of abiraterone as first-line therapy for advanced prostate cancer.

ASCO 2017: Psychological Intervention Lowers Survivors’ Fear of Cancer Recurrence

Truckee, CA (UroToday.com) About 50% of all cancer survivors and 70% of young breast cancer survivors report moderate to high fear of recurrence. The fear can be so distressing that it negatively affects medical follow-up behavior, mood, relationships, work, goal setting, and quality of life. Yet, interventions to alleviate this fear are lacking.

ASCO 2017: Psychological Intervention Relieves Distress in Patients With Advanced Cancer

Truckee, CA (UroToday.com) Advanced cancer triggers enormous distress and brings challenges that can seem overwhelming. Yet, most cancer centers lack systematic approaches to help patients and families manage the practical and emotional toll of advanced cancer. Findings from a randomized clinical trial of 305 patients with advanced cancer suggest that a brief psychological intervention, called Managing Cancer And Living Meaningfully (CALM), could help fill this need.

ASCO 2017: Remote Therapy Program Improves Quality of Life, Lowers Distress After Cancer Diagnosis

Truckee, CA (UroToday.com) Most patients experience significant distress after they are diagnosed with cancer. This distress not only erodes quality of life, but can also negatively affect the course of the disease and the patient’s ability to tolerate treatment. Yet, few patients with cancer receive psychological support. A prospective study shows that a web-based stress management program can relieve distress and markedly improve quality of life for patients.

ASCO 2017: A Single Radiation Treatment Sufficiently Relieves Spinal Cord Compression Symptoms

Truckee, CA (UroToday.com) A common complication in people with metastatic cancer, spinal cord compression is a major detriment to quality of life. Radiation treatment is widely used to relieve pain and other symptoms, but there is no standard recommended schedule, and approaches currently vary. Findings from a phase III clinical trial show that a single radiation treatment is as effective as a full week of radiation.

Page 1 of 2

ASCO 2017 Press Releases

Free Daily and Weekly newsletters offered by content of interest

Login